Evaluation of Motor Imagery, Cognitive Function and Reaction Time in Children With Bronchiectasis
NCT06630403, Completed, Atlas University
Trial 9
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Evaluation of Motor Imagery, Cognitive Function and Reaction Time in Children With Bronchiectasis | ClinicalTrials.gov |
| NCT number | NCT06630403 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Enrollment | 40 participants, actual | ClinicalTrials.gov |
| Lead sponsor | Atlas University | ClinicalTrials.gov |
| Conditions | Bronchiectasis | ClinicalTrials.gov |
| Interventions | Demographic Data, Disease History, Pulmonary Function Test, Reaction Time, Functional Capacity, Dyspnea Perception, Quality of Life, Fear of movement, Ability of Motor Imagery, Cognitive Functions | ClinicalTrials.gov |
| First posted | 2024-10-08 | ClinicalTrials.gov |
| Last updated | 2024-10-08 | ClinicalTrials.gov |
Registered outcomes 12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Trail Making Test | The assessment will be administered only once to each participant. All tests will take place on the same day and will last approximately 60 minutes. | The Trail Making Test is divided into two parts. In the first part, the participant is asked to connect the 23 numbers in the circle randomly placed on the page with a pencil in an orderly order, and in the second part, the participant is asked to draw and connect the 23 numbers and letters in the circle in a mixed order. In the second part, the individual has to change sets between one letter and one number. (1- A, 2-B, 3-C, 4-D, etc.).The test can be applied between the ages of 8-79. | ClinicalTrials.gov |
| Primary | Stroop Test | The assessment will be administered only once to each participant. All tests will take place on the same day and will last approximately 60 minutes. | The Stroop Test consists of four parts. The first part contains words written in black (e.g blue), the second part contains colors and the last part contains words written in different colors (e.g. the word blue written in red ink). The participant is expected to fulfill these tasks in turn. The participant has to correctly read the words in the first part, say the colors in the next part, read the colored word in the third part, and then say the color in which the word is written in the last part. | ClinicalTrials.gov |
| Primary | Nelson Hand Reaction Test | The assessment will be administered only once to each participant. All tests will take place on the same day and will last approximately 60 minutes. | The tester holds the ruler by the tip and between the thumb and index fingers of the subject and releases the ruler. When the ruler is released, the participant is asked to catch the ruler. The participants hand is fixed and 20 trials are performed in the test. At the top point where the subject grabs the ruler with his/her fingers, the reaction time of the subject is determined. The highest and lowest five trials are discarded and the remaining ones are averaged. | ClinicalTrials.gov |
| Primary | Nelson Foot Reaction Test | The assessment will be administered only once to each participant. All tests will take place on the same day and will last approximately 60 minutes. | The participant removes his/her shoes and sits with the toe 2.5 cm from the wall and the heel 5 cm. The tester holds the reaction time ruler at the edge of the wall and between the wall and the subjects foot, with the baseline at the tip of the thumb. The subject is instructed to look at the concentration line and to hold the ruler, which falls after the ready command, by pinching it against the wall with the toe of the foot. This test is repeated 20 times. | ClinicalTrials.gov |
| Primary | Movement Imagery Questionnaire-3 | The assessment will be administered only once to each participant. All tests will take place on the same day and will last approximately 60 minutes | It consists of 3 subscales evaluating external visual imagery, internal visual imagery and kinesthetic imagery and a total of 12 items. Before scoring each movement, the participant is asked to perform the movement and then the movement is imaged three times. Scoring is done between 1 and 7, with "1 point: very difficult to see/feel, 7 points: very easy to see/feel". A maximum score of 84 can be obtained on the MIQ-3 questionnaire. A higher score on the test means that the person has a better ability to visualize. | ClinicalTrials.gov |
| Primary | Vividness of Motion Imagery Questionnaire | The assessment will be administered only once to each participant. All tests will take place on the same day and will last approximately 60 minutes | In the Vividness of Movement Imagery questionnaire, the person does not need to perform the movements before visualizing them. This scale consists of four scenarios and you are asked to rank on a scale of one to five how vividly you picture them in the participant mind. Each scenario asks you to imagine the face of a loved one, a view of your favorite grocery store or a beautiful landscape and rate the vividness of the details in each scene. The individual is asked to imagine 4 scenarios first with eyes open and then with eyes closed. As a result of this situation, the individual can reach a maximum of 160 in total score. | ClinicalTrials.gov |
| Secondary | Dalhousie Dyspnea and Perceived Exertion Scale | The assessment will be administered only once to each participant. All tests will take place on the same day and will last approximately 60 minutes. | It consists of seven pictures each showing the three dyspnea constructs (chest tightness, throat closure and effort to breathe), plus an additional pictorial scale showing leg effort. | ClinicalTrials.gov |
| Secondary | 6 Minute Walk Test | The assessment will be administered only once to each participant. All tests will take place on the same day and will last approximately 60 minutes. | 6MWT is defined as a submaximal test that can be easily applied in healthy or unhealthy individuals and is evaluated as an indicator of exercise capacity and walking capacity as well as many cardiovascular diseases. The 6MWT is referred to as the "Gold Standard" test of walking capacity. The aim of this test is to reach the longest possible walking distance at the end of six minutes. The standard protocol is applied in a 30-meter uninterrupted corridor or open area. It is recommended to repeat the 6MWT three times on the same day with a one-hour rest interval; the maximum walking distance is taken into account. | ClinicalTrials.gov |
| Secondary | Quality of Life Scale for Children | The assessment will be administered only once to each participant. All tests will take place on the same day and will last approximately 60 minutes. | This scale consists of a total of 23 items and 4 subscales, including 8 items measuring physical functioning, 5 items measuring emotional functioning, 5 items measuring social functioning and 5 items assessing school functioning. In the instructions in the scale, it is asked to determine how much the issue mentioned in the items has been a problem for the parent or child in the last month. Answers are given on a 5-point ordinal scale (0=never, 1=rarely, 2=sometimes, 3=often, 4=almost always). By inverting the scores (e.g. 0 → 100, 1 → 75, 2 → 50, 3 → 25, 4 → 0), a quality of life score between 0% and 100% is calculated for each section. A high score means that the participant has a high quality of life. | ClinicalTrials.gov |
| Secondary | Tampa Kinesiophobia Scale | The assessment will be administered only once to each participant. All tests will take place on the same day and will last approximately 60 minutes. | It is a 17-question scale developed to measure fear of movement/reinjury. The scale includes parameters of injury/re-injury and fear-avoidance in work-related activities. The scale uses a 4-point Likert scale (1=strongly disagree, 4=strongly agree). A high score on the scale indicates a high level of kinesiophobia. A score of 37 and above indicates kinesiophobia (fear of movement). | ClinicalTrials.gov |
| Secondary | Respiratory Function Test | The assessment will be administered only once to each participant. All tests will take place on the same day and will last approximately 60 minutes. | Pulmonary function will be evaluated with a spirometer according to the American Thoracic Society and European Respiratory Society criteria. The device replaces the hand-held flow sensor, traditionally placed in the mouth, with the same sensor being secured to the face using straps and a mask. Participants will be asked to take a deep breath and then perform a strong and complete exhalation. This maneuver will be repeated three times, and the best of the three measurements, with a difference of less than 0.150 L between them, will be recorded. The participants; forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), Tiffeneau ratio (FEV1/FVC), peak expiratory flow (PEF), and forced expiratory flow at 25-75% (FEF25-75%) will be measured. When data such as age, gender, race, height, and weight are entered into the device, the expected values of all parameters will be calculated based on normative values. | ClinicalTrials.gov |
| Secondary | Demographic and Clinical Data Collection Form | The assessment will be administered only once to each participant. All tests will take place on the same day and will last approximately 60 minutes. | Participants; gender, date of birth, height in meters, weight in kilograms, body mass index in kg/m2, contact information, date and method of diagnosis, presence of chronic disease, medications/devices used, number of acute exacerbations and hospitalization history of the patient in the last year, presence of disease symptoms, previous surgery/trauma history, previous physiotherapy and rehabilitation program, background and family history information will be recorded. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 3
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Stroop Color-Word Test | Primary outcome | ConductCognition |
| Trail Making Test A | Primary outcome | ConductCognition |
| Trail Making Test B | Primary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)